SPEC — SpectraCure AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK24.82m
- SEK26.10m
- SEK0.87m
Brief: SpectraCure Rights Issue Subscribed To 58.10%
Brief: SpectraCure Announces Preliminary Results From Prostate Cancer Study
Brief: Spectracure Gets Approval From German Drug Authority For Prostate Cancer Study
Brief: Spectracure Signs Deal With Cologne University For Prostate Cancer Study
Brief: SpectraCure: Subscription Price In Rights Issue Set At SEK 0.18 Per Unit
Brief: SpectraCure Says Rights Issue Subject To May 30 Meeting Approval
Brief: Spectracure Buys Rights To Patent Application From KTH
Brief: Spectracure Signs Agreement With MSKCC For Prostate Cancer Study
Brief: Spectracure Q2 Loss After Tax Widens To SEK 6.1 Mln
Brief: Spectracure Q1 Loss After Tax Widens To SEK 6.0 Mln
Brief: Spectracure Q4 Loss After Tax SEK 4.4 Million
Brief: SpectraCure Q3 Loss After Tax Narrows To SEK 4.7 Mln
Brief: Spectracure To Seek Approval For Clinical Study Of Primary Prostate Cancer
Brief: SpectraCure Q2 Loss After Tax Narrows To SEK 6.0 Mln
Brief: Spectracure Q1 Loss After Tax Narrows To SEK 5.4 Mln
Brief: Spectracure Q4 Net Loss Widens To SEK 6.4 Million
Brief: SpectraCure Appoints Masoud Khayyami As CEO
Brief: Spectracures Signs LoI With Cheplapharm
Brief: SpectraCure Q3 Net Loss Narrows To SEK 5.6 Million